| Name | Ursodiol | ||
| PubChem CID | 31401 | ||
| Molecular Weight | 392.6g/mol | ||
| Synonyms |
3 alpha,7 beta Dihydroxy 5 beta cholan 24 oic Acid, 3 alpha,7 beta-Dihydroxy-5 beta-cholan-24-oic Acid, Acid, Deoxyursocholic, Acid, Ursacholic, Acid, Ursodeoxycholic, Cholit-Ursan, Cholofalk, Delursan, Deoxyursocholic Acid, Destolit, Sodium Ursodeoxycholate, Urdox, Ursacholic Acid, Urso, Urso Heumann, Ursobilane, Ursochol, Ursodeoxycholate, Sodium, Ursodeoxycholic Acid, Ursodiol, Ursofalk, Ursogal, Ursolite, Ursolvan |
||
| Formula | C₂₄H₄₀O₄ | ||
| SMILES | CC(CCC(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C | ||
| InChI | 1S/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1 | ||
| InChIKey | RUDATBOHQWOJDD-UZVSRGJWSA-N | ||
| CAS Number | 128-13-2 | ||
| ChEMBL ID | CHEMBL1551 | ||
| ChEBI ID | CHEBI:9907 | ||
| Drug Bank ID | DB01586 | ||
| KEGG ID | C07880 | ||
| Toxicity | Organism | Test Type | Route(Dose) |
| rat | LD50 | intraperitoneal(165 mg/kg) | |
| mouse | LD50 | intraperitoneal(254 mg/kg) | |
| rat | LD50 | oral(322 mg/kg) | |
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | XiongDan | ||
| Use Part | Gall bladder | ||
| Flavor | Bitter | ||
| Meridian Tropism | Liver; Heart; Gallbladder | ||
| Species |
>Kingdom: Metazoa
-->Phylum: Chordata
-->Class: Mammalia
-->Order: Primates
-->Family: Hominidae
-->Genus: Homo
-->Species: Homo sapiens
|
||
| Pair Name | Ursodiol, Bortezomib | |||
| Partner Name | Bortezomib | |||
| Disease Info | [ICD-11: 2A00] | Glioblastoma multiforme | Investigative | |
| Biological Phenomena | Induction-->Endoplasmic reticulum stress | |||
| Gene Regulation | Up-regulation | Expression | ATF4 | hsa468 |
| Up-regulation | Expression | DDIT3 | hsa1649 | |
| Up-regulation | Expression | EIF2AK3 | hsa9451 | |
| Up-regulation | Expression | ROS1 | hsa6098 | |
| In Vitro Model | A-172 | Glioblastoma | Homo sapiens (Human) | CVCL_0131 |
| LN-229 | Glioblastoma | Homo sapiens (Human) | CVCL_0393 | |
| U-87MG ATCC | Glioblastoma | Homo sapiens (Human) | CVCL_0022 | |
| U-251MG | Astrocytoma | Homo sapiens (Human) | CVCL_0021 | |
| Result | Ursodeoxycholic Acid Inhibits Glioblastoma Progression via Endoplasmic Reticulum Stress Related Apoptosis and Synergizes with the Proteasome Inhibitor Bortezomib | |||
| Pair Name | Ursodiol, Sorafenib | |||
| Partner Name | Sorafenib | |||
| Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Up-regulation | Phosphorylation | MAPK1 | hsa5594 |
| Down-regulation | Phosphorylation | STAT3 | hsa6774 | |
| In Vitro Model | Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 |
| Result | The present findings may represent a promising therapeutic strategy for patients with advanced hepatocellular carcinoma. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Ursodeoxycholic Acid Inhibits Glioblastoma Progression via Endoplasmic Reticulum Stress Related Apoptosis and Synergizes with the Proteasome Inhibitor Bortezomib. ACS Chem Neurosci. 2020 May 6;11(9):1337-1346. doi: 10.1021/acschemneuro.0c00095. | Click |
| 2 | Synergistic effect of ursodeoxycholic acid on the antitumor activity of sorafenib in hepatocellular carcinoma cells via modulation of STAT3 and ERK. Int J Mol Med. 2018 Nov;42(5):2551-2559. doi: 10.3892/ijmm.2018.3807. | Click |
